Ken Theliver

Research Analyst at Brookline Capital Markets

Kemp Dolliver is the Director of Research and Senior Analyst at Brookline Capital Markets, specializing in healthcare sector equity research, with a particular focus on emerging markets and radiopharmaceuticals. He covers a range of healthcare companies including BIOX and IceCure Medical, and holds a TipRanks track record with approximately 31% profitable recommendations and an average return per transaction of -6.9%. Dolliver began his career in portfolio management at Aetna and Bank of America before taking sell-side research roles as Managing Director at Cowen Inc., Avondale Partners LLC, and Religare Capital Markets; he later founded Cherrystone Hill Capital Management prior to joining Brookline. He holds a CFA designation, an MBA from the Darden School of Business at the University of Virginia, and a BS in Commerce from the McIntire School of Commerce, and has been recognized four times by The Wall Street Journal for his stock picking performance.